The DOI matches its Crossref record.
Ziconotide: Neuronal Calcium Channel Blocker for Treating Severe Chronic Pain
Abstract
Ziconotide (PRIALT®) is a neuroactive peptide in the final stages of clinical development as a novel non-opioid treatment for severe chronic pain. It is the synthetic equivalent of ω-MVIIA, a component of the venom of the marine snail, Conus magus. The mechanism of action underlying ziconotides therapeutic profile derives from its potent and selective blockade of neuronal N-type voltage-sensitive calcium channels (NVSCCs). Direct blockade of N-VSCCs inhibits the activity of a subset of neurons, including pain-sensing primary nociceptors. This mechanism of action distinguishes ziconotide from all other analgesics, including opioid analgesics. In fact, ziconotide is potently anti-nociceptive in animal models of pain in which morphine exhibits poor anti-nociceptive activity. Moreover, in contrast to opiates, tolerance to ziconotide is not observed. Clinical studies of ziconotide in more than 2,000 patients reveal important correlations to ziconotides non-clinical pharmacology. For example, ziconotide provides significant pain relief to severe chronic pain sufferers who have failed to obtain relief from opiate therapy and no evidence of tolerance to ziconotide is seen in these patients. Contingent on regulatory approval, ziconotide will be the first in a new class of neurological drugs: the N-type calcium channel blockers, or NCCBs. Its novel mechanism of action as a non-opioid analgesic suggests ziconotide has the potential to play a valuable role in treatment regimens for severe chronic pain. If approved for clinical use, ziconotide will further validate the neuroactive venom peptides as a source of new and useful medicines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Future of Peptide‐based Drugs
Craik, D. J., Fairlie, D. P., Liras, S., & Price, D. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12055 · Cited by 1,979
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 1,964
Drug development from marine natural products
Molinski, T. F., Dalisay, D. S., Lievens, S. L., & Saludes, J. P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2487 · Cited by 1,186
Zamponi, G. W., Striessnig, J., Koschak, A., & Dolphin, A. C. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009654 · Cited by 1,103
The odyssey of marine pharmaceuticals: a current pipeline perspective
Mayer, A. M. S., Glaser, K. B., Cuevas, C., Jacobs, R. S., Kem, W., Little, R. D., McIntosh, J. M., Newman, D. J., Potts, B. C., & Shuster, D. E. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.02.005 · Cited by 666
Multifaceted Roles of Disulfide Bonds. Peptides as Therapeutics
Góngora-Benítez, M., Tulla-Puche, J., & Albericio, F. (2014) · Chemical Reviews · doi:10.1021/cr400031z · Cited by 655
Bioactive Peptides: Synthesis, Sources, Applications, and Proposed Mechanisms of Action
Akbarian, M., Khani, A., Eghbalpour, S., & Uversky, V. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031445 · Cited by 612
Gentilucci, L., De Marco, R., & Cerisoli, L. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210793292555 · Cited by 586
Venoms as a platform for human drugs: translating toxins into therapeutics
King, G. F. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.621940 · Cited by 516
The emergence of peptides in the pharmaceutical business: From exploration to exploitation
Uhlig, T., Kyprianou, T., Martinelli, F. G., Oppici, C. A., Heiligers, D., Hills, D., Calvo, X. R., & Verhaert, P. (2014) · EuPA Open Proteomics · doi:10.1016/j.euprot.2014.05.003 · Cited by 456
Marine Natural Products: A New Wave of Drugs?
Montaser, R., & Luesch, H. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.118 · Cited by 437
Conus Venom Peptide Pharmacology
Lewis, R. J., Dutertre, S., Vetter, I., & Christie, M. J. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005322 · Cited by 424
Targeting voltage-gated calcium channels in neurological and psychiatric diseases
Zamponi, G. W. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.5 · Cited by 368
Ziconotide for treatment of severe chronic pain
Schmidtko, A., Lötsch, J., Freynhagen, R., & Geisslinger, G. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60354-6 · Cited by 356
Calcium-Permeable Ion Channels in Pain Signaling
Bourinet, E., Altier, C., Hildebrand, M. E., Trang, T., Salter, M. W., & Zamponi, G. W. (2014) · Physiological Reviews · doi:10.1152/physrev.00023.2013 · Cited by 337
Large‐scale species delimitation method for hyperdiverse groups
PUILLANDRE, N., MODICA, M. V., ZHANG, Y., SIROVICH, L., BOISSELIER, M. ‐., CRUAUD, C., HOLFORD, M., & SAMADI, S. (2012) · Molecular Ecology · doi:10.1111/j.1365-294x.2012.05559.x · Cited by 335
Discovery, Synthesis, and Structure–Activity Relationships of Conotoxins
Akondi, K. B., Muttenthaler, M., Dutertre, S., Kaas, Q., Craik, D. J., Lewis, R. J., & Alewood, P. F. (2014) · Chemical Reviews · doi:10.1021/cr400401e · Cited by 323
4-Thiazolidinones: The advances continue…
Tripathi, A. C., Gupta, S. J., Fatima, G. N., Sonar, P. K., Verma, A., & Saraf, S. K. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.11.017 · Cited by 319
Ziconotide: a review of its pharmacology and use in the treatment of pain
McGivern, J. G. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2007.3.1.69 · Cited by 310
Celie, P. H. N., Kasheverov, I. E., Mordvintsev, D. Y., Hogg, R. C., van Nierop, P., van Elk, R., van Rossum-Fikkert, S. E., Zhmak, M. N., Bertrand, D., Tsetlin, V., et al. (2005) · Nature Structural & Molecular Biology · doi:10.1038/nsmb951 · Cited by 310
Conus Peptides: Biodiversity-based Discovery and Exogenomics
Olivera, B. M. (2006) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)84029-2 · Cited by 302
Spider-Venom Peptides as Therapeutics
Saez, N. J., Senff, S., Jensen, J. E., Er, S. Y., Herzig, V., Rash, L. D., & King, G. F. (2010) · Toxins · doi:10.3390/toxins2122851 · Cited by 298
The chemistry of snake venom and its medicinal potential
Oliveira, A. L., Viegas, M. F., da Silva, S. L., Soares, A. M., Ramos, M. J., & Fernandes, P. A. (2022) · Nature Reviews Chemistry · doi:10.1038/s41570-022-00393-7 · Cited by 289
Schendel, V., Rash, L. D., Jenner, R. A., & Undheim, E. A. B. (2019) · Toxins · doi:10.3390/toxins11110666 · Cited by 285
Chemokines: Integrators of Pain and Inflammation
White, F. A., Bhangoo, S. K., & Miller, R. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1852 · Cited by 280
Peptide therapeutics from venom: Current status and potential
Pennington, M. W., Czerwinski, A., & Norton, R. S. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.09.029 · Cited by 278
The potential role of lamotrigine in schizophrenia
Large, C. H., Webster, E. L., & Goff, D. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0020-9 · Cited by 69
Peptide design through binding interface mimicry with PepMimic
(2025) · doi:10.1038/s41551-025-01507-4 · Cited by 30
Targeting Dysregulated Ion Channels in Liver Tumors with Venom Peptides
Achimba, F., Faezov, B., Cohen, B., Dunbrack, R., & Holford, M. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0256 · Cited by 6
Metadata
- Authors
- Miljanich, G. P.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2004-12-01
- Volume
- 11
- Issue
- 23
- Pages
- 3029-3040
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2092424786
- Cited by
- 607
- References
- 0
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.